Add Yahoo as a preferred source to see more of our stories on Google. It’s been said before and it’s true: a healthy scalp is key to healthy hair. But for those dealing with pesky and sometimes ...

Please provide your email address to receive an email when new articles are posted on . This decision makes Zoryve the first drug approved in this indication with a new mechanism of action in more ...

Please provide your email address to receive an email when new articles are posted on . The FDA will review a new drug application for roflumilast foam 0.3% to treat seborrheic dermatitis in patients ...

WESTLAKE VILLAGE, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...

Seborrheic dermatitis can be a stubborn condition to treat, but lifestyle changes, home remedies, and over-the-counter products, including certain shampoos and conditioners, can all be helpful, ...

Though seborrheic dermatitis is an inflammatory condition that most commonly presents on the scalp, its can affect other areas of your body, such as your ears, eyebrows, eyelids, chest, back, armpits, ...

Credit: Arcutis Biotherapeutics. Zoryve topical foam is supplied in a 60-gram pressurized aluminum can. Zoryve ® (roflumilast) topical foam, 0.3% is now available for the treatment of seborrheic ...

Arcutis Biotherapeutics, Inc. ARQT announced that the FDA has approved the new drug application (NDA) for Zoryve (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis in patients ...

This article was reviewed by Knox Beasley, MD. Flakes on your scalp making you feel self-conscious? Let’s talk about seborrheic dermatitis vs dandruff. Whether your scalp feels like a snowglobe thanks ...

Add Yahoo as a preferred source to see more of our stories on Google. If the skin under your facial hair is often red, irritated, itchy or flaky, the culprit could be a condition called seborrheic ...

The US Food and Drug Administration (FDA) has agreed to review a new drug application (NDA) for roflumilast foam 0.3% for treating seborrheic dermatitis in patients ages 9 years and older. If approved ...